Dr. Hawley received a B.S. in Chemical Physics from Queen’s University in Kingston, Ontario, Canada in 1979 and, after graduate studies at the Ontario Cancer Institute under the supervision of Dr. Nobumichi Hozumi, obtained his Ph.D. in Medical Biophysics from the University of Toronto in 1984. Following three years of postdoctoral training in developmental hematopoiesis with Dr. Beatrice Mintz at the Fox Chase Cancer Center in Philadelphia as a Fellow of the Medical Research Council of Canada, Dr. Hawley returned to Canada where he was a Career Scientist of the Ontario Cancer Treatment and Research Foundation, first at the Ottawa Cancer Center and subsequently in the Cancer Biology Division of the University of Toronto’s Sunnybrook Health Science Center. In January 1996, Dr. Hawley moved to the Toronto General Hospital where he was Scientific Director of the Oncology Gene Therapy Program and Head of the Oncology Research Laboratories. He held these positions and was an Associate Professor of Medical Biophysics and Medicine at the University of Toronto until January 1999, when he joined the Jerome H. Holland Laboratory for the Biomedical Sciences in Rockville, Maryland—the national research and development division of American Red Cross Biomedical Services—to lead the newly created Hematopoiesis Department. Dr. Hawley was appointed to the faculty of The George Washington University School of Medicine and Health Sciences as Professor of Anatomy and Cell Biology in December 1999 in accordance with an Affiliation Agreement between GW and the Red Cross. In January 2002, Dr. Hawley was named Executive Director of Cell Therapy Research and Development at the Red Cross, assuming leadership of the Holland Laboratory’s Blood and Cell Therapy Development Department while maintaining his position as Head of the Hematopoiesis Department.
Dr. Hawley’s research is concerned with basic aspects and experimental therapeutics involving normal and malignant cells of the hematopoietic system. He has published over 170 original and review articles on stem cell and regenerative biology, gene therapy modeling, molecular pathogenesis of leukemia, and drug resistance mechanisms in multiple myeloma. Together with Teresa Hawley, he edited the second and third editions of Flow Cytometry Protocols, Volumes 263 and 699 in the Methods in Molecular Biology series published by Humana Press/Springer. Dr. Hawley is best known for developing the MSCV (murine stem cell virus) retroviral vector which has been utilized for stem cell and somatic cell gene transfer experiments in thousands of scientific publications. His current research focus is multiple myeloma, an incurable clonal plasma cell disorder which is the second most common hematologic malignancy in the United States and the most common hematologic malignancy among African Americans.